YC-1: Soluble Guanylyl Cyclase Activator & HIF-1α Inhibitor for Cancer and Hypoxia Research

Executive Summary: YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is a crystalline small molecule well-characterized as both a soluble guanylyl cyclase (sGC) activator and an inhibitor of hypoxia-inducible factor-1α (HIF-1α) expression, with an IC50 of 1.2 µM for HIF-1 transcriptional activity in vitro (APExBIO). It blocks HIF-1α at the post-transcriptional level, suppressing tumor angiogenesis and growth in preclinical models. YC-1 is highly soluble in DMSO (≥30.4 mg/mL), making it suitable for diverse laboratory workflows. Its dual activity enables targeted research into cancer, hypoxia signaling, and the cGMP signaling pathway (Llamab.com). The compound is supplied by APExBIO at ≥98% purity and has defined biophysical and storage properties to ensure experimental reproducibility.

Biological Rationale

Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor that mediates cellular adaptation to low oxygen. It regulates genes involved in angiogenesis (such as VEGF), glucose metabolism, and cell survival under hypoxic conditions—key processes in tumor progression and metastasis (Elama et al., 2021). Overexpression of HIF-1α is correlated with aggressive tumor phenotypes and therapy resistance. Targeting HIF-1α via small-molecule inhibition is a validated strategy for impairing tumor growth and angiogenesis. Soluble guanylyl cyclase (sGC) is a cytosolic enzyme that generates cyclic GMP (cGMP) upon nitric oxide stimulation. cGMP mediates vascular relaxation, inhibits platelet aggregation, and modulates smooth muscle function. By activating sGC, YC-1 influences both vascular function and antitumor responses, providing a unique intersection between cancer biology and vascular pharmacology (deae-dextran.com).

Mechanism of Action of YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol

• HIF-1α inhibition: YC-1 downregulates HIF-1α protein levels post-transcriptionally under hypoxic conditions, preventing the activation of downstream hypoxia-responsive genes.
• Blockade of HIF-1 transcriptional activity: YC-1 impairs HIF-1-mediated gene expression with an IC50 of 1.2 µM in hypoxic cell models (APExBIO).
• sGC activation: YC-1 binds to and stimulates sGC independent of nitric oxide, leading to increased intracellular cGMP, which results in vasodilation and antiplatelet effects.

Importantly, HIF-1α inhibition is mediated by mechanisms distinct from sGC activation, allowing dual-pathway interrogation in research settings (More details—this extends prior mechanistic reviews by emphasizing recent post-transcriptional insights).

Evidence & Benchmarks

• YC-1 inhibits HIF-1α expression at the post-transcriptional level in multiple cancer cell lines, leading to suppression of HIF-1-dependent gene expression (APExBIO, product page).
• IC50 for inhibition of hypoxia-induced HIF-1 transcriptional activity is 1.2 µM in vitro (APExBIO, product page).
• In vivo administration leads to reduced tumor size and vascularization in animal models, with decreased expression of HIF-1α and angiogenic markers (mito-egfp-probe.com).
• YC-1 activates sGC, increasing cGMP and inhibiting platelet aggregation and vascular contraction in ex vivo and in vitro assays (Elama et al., 2021).
• Solubility: ≥30.4 mg/mL in DMSO, ≥16.2 mg/mL in ethanol, insoluble in water (APExBIO, specification).
• Supplied as crystalline solid, molecular weight 304.34, purity ≥98%, stable at room temperature for long-term storage as solid (APExBIO, product data).

Applications, Limits & Misconceptions

YC-1 is widely used in basic and translational research to dissect the hypoxia signaling pathway, study apoptosis mechanisms, and model tumor angiogenesis. It is also applied in pharmacological studies on the cGMP signaling pathway and vascular biology (laminin-925-933.com). This article updates and clarifies the practical boundaries and best-use scenarios compared to prior application notes.

Common Pitfalls or Misconceptions

• YC-1 is not a direct cytotoxic agent; its anticancer effects are mediated via pathway inhibition, not genotoxicity.
• It is not suitable for direct clinical or diagnostic applications; research use only.
• YC-1 is insoluble in water and requires DMSO or ethanol as solvents for biological assays; improper solvent use can affect assay results.
• Long-term storage of YC-1 solutions is not recommended due to stability concerns; fresh aliquots should be prepared (APExBIO).
• The compound's sGC activation is distinct from its HIF-1α inhibition; effects on cGMP should not be conflated with hypoxia pathway modulation.

Workflow Integration & Parameters

For cell-based assays, YC-1 is typically dissolved in DMSO at stock concentrations of 10–50 mM, then diluted to working concentrations (e.g., 0.5–10 µM) in culture media. Ensure final DMSO concentration does not exceed 0.1% to avoid cytotoxicity. APExBIO's B7641 kit provides ≥98% purity crystalline material, minimizing batch-to-batch variability (YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol product page).

For in vivo work, dosing regimens and vehicles should be validated for the animal model. Fresh solutions should be prepared immediately prior to use. Storage at room temperature is recommended for the solid compound, with solutions kept on ice and protected from light until use (immunoglobulin-light-chain-variable-region-fragment.com—this scenario-driven guide demonstrates troubleshooting steps not covered here).

Conclusion & Outlook

YC-1 (SKU B7641, APExBIO) is a validated tool for dissecting hypoxia and cGMP signaling in cancer and vascular biology. Its dual mechanism enables precise modeling of tumor microenvironment adaptations. As research advances toward targeted therapies and pathway-specific interventions, compounds such as YC-1 remain indispensable for mechanistic and translational studies. For detailed protocols and scenario-based troubleshooting, see YC-1: A Powerful HIF-1α Inhibitor for Cancer & Hypoxia Research, which discusses workflow optimization not addressed here.